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Accelerated radiotherapy prevent local relapse in molecular unfavourable breast cancer?
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Introduction. Molecular classiﬁcation is at present a useful tool to predict clinical outcome in breast cancer. Triple negative and
Her-2+ groups had worse survival and reduced local control after radiotherapy in patients treated by conventional fractionation,
probably through increased repopulation during the radiotherapy course.
Objective. The aim of the present study is whether accelerated hypofractionation breast irradiation can increase local control in
those bad prognosis molecular classiﬁed tumours.
Methods and materials. From January 2008 to December 2011, 399 patients with inﬁltrating breast carcinomas treated with con-
servatively surgery, were prospectively included. Mean age: 55.2, median: 54 (range 24–88 years old), 72.4% menopausal. DCI
(88.7%), cT1 (58.64%), cN0 (76.2%), and RE+ 81.2% and RP+ 87.9%. Her-2/neu+ (19.8%). Four patient groups were deﬁned by receptor
status: Group 1: Luminal A 121 (30.3%), Group 2: Luminal B 206 (51.6%), Group 3: Her-2+ 24 (6%), and Group 4: Triple N 48 (12%).
255 patients were initially referred to surgery and 144 received neoadjuvant treatment due to locally advanced disease. All were
treated by accelerated hypofractionation on the tumoral bed by a 2.35Gy/frx scheme. Those with negative margins received 47Gy
in 20 frx, those at moderate risk 58.75Gy in 25 frx and most of those with higher risk (very close or affected margins) 63.45Gy in
27 frx. Treatment acceleration allows a planned total treatment time of 28, 35 or 37 days respectively.
Results. After a mean follow-up: 30.85±13.45, median: 31 months (range 6–66) the 4 years ipsilateral tumour control rate was
95.51±0.02%. For those patients initially referred to surgery no differences were found in local control regarding molecular
subtypes: 93% vs 92.3%, p=0.441. Patients with locally advanced tumours initially treated with neoadjuvant chemotherapy high
risk subtypes did worse (89.4%) than luminal cases (98.2%) p=0.054.
Conclusion. Accelerated hypofractionated radiotherapy seems to be useful though preventing tumour repopulation for bad prog-
nosis molecular subtypes in early tumours. Longer follow-up will be needed to conﬁrm these encouraging results.
http://dx.doi.org/10.1016/j.rpor.2013.03.717
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Introduction. Axillary dissection is the standard treatment in patients with breast cancer and positive sentinel lymph node.
According to the literature in 40–70% of the lymphadenectomies, the sentinel node was the only nodal metástasis, implying
potential complications due to the intervention. Several groups have developed models to predict the likelihood of non-sentinel
node involvement in patients with positive sentinel biopsy.
Objectives. To determine the area under the ROC curve and predictive efﬁciency of the Memorial Sloan-Kettering Cancer Center,
Stanford, Tenon and Cambridge models in patients of The General Hospital of Catalunya.
Methods. We studied retrospectively the performance of the models in 48 patients at our hospital from October 2002 to December
2012, who met the following criteria: invasive primary breast cancer without clinical nodal affection, positive sentinel biopsy
and lack of neoadjuvant treatment before sentinel node biopsy or lymph node dissection.
Results. According to the literature, we observed that 62.5% of GC (+) and 76.5% of GC micrometastasis (+) had negative lym-
phadenectomy. The area under the ROC curve for the MSKCC, Stanford, Tenon and Cambridge models was 0.609 (IC95%
0.449–0.769), 0.642 (IC95% 0.479–0.805), 0.539 (IC95% 0.375–0.703) and 0.560 (IC95% 0.395–0.725) respectively. The cut-off points
for higher efﬁcient diagnostic of the MSKCC, Stanford, Cambridge and Tenon models were in a predicted probability of 12.5%
(sensitivity 94.4% and speciﬁcity 33.3%), 12.2% (sensitivity 94.4% and speciﬁcity 23.3%), 16.8% (sensitivity 94.4% and speciﬁcity
20%) and Tenon score 2.75 (sensitivity 94.4% and speciﬁcity 30%) respectively.
Conclusions. We did not observe any area under the ROC curve greater than 0.70, therefore these models should not be applied to
our population. Further research is needed to conﬁrm that the omission of lymphadenectomy is safe and if the optimization of
the cut-off points could reduce the false positive results when counseling patients about their risk of additional nodal disease.
http://dx.doi.org/10.1016/j.rpor.2013.03.718
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One of themost important prognostic indicators in patientswith breast cancer is axillary lymphnode status. Sentinel lymphnode
(SLN) biopsy has emerged as a potential alternative to routine axillary dissection in clinically node-negative early breast cancer.
